Zentalis Pharmaceuticals (ZNTL) Retained Earnings (2019 - 2026)

Zentalis Pharmaceuticals' Retained Earnings history runs 8 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 11.26% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (down 11.26% YoY), while the FY2025 annual figure was $196000.0, down 64.87% from the prior year.
• Retained Earnings was -$1.2 billion for Q1 2026 at Zentalis Pharmaceuticals, down from $196000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $2.2 million in Q4 2023 to a low of -$1.2 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$518.5 million across 5 years, with a median of -$596.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings tumbled 837372.0% in 2022, then jumped 100.37% in 2023.
• A 5-year view of Retained Earnings shows it stood at -$596.4 million in 2022, then surged by 100.37% to $2.2 million in 2023, then tumbled by 74.57% to $558000.0 in 2024, then slumped by 64.87% to $196000.0 in 2025, then plunged by 626021.94% to -$1.2 billion in 2026.
• The last three Retained Earnings figures came in at -$1.2 billion (Q1 2026), $196000.0 (Q4 2025), and $186000.0 (Q3 2025), per Business Quant data.